High immunoexpression of progesterone-induced blocking factor (PIBF) in endometrial cancer

Purpose of Investigation: This study aims to investigate PIBF expression levels in normal, hyperplastic, and endometrioid adenocarcinoma paraffin blocks. The purpose of this study is to determine the PIBF expression levels in endometrial cancer cells. Materials and Methods: A total of 90 patients were investigated. Thirty of those were diagnosed as having normal endometrial tissue, 30 had endometrial hyperplasia, and 30 had endometrioid adenocarcinoma. The expression of PIBF was assessed using immunohistochemically using paraffin-embedded tissue blocks. Results: Tissue sections were compared based on immunostaining with PIBF. The authors detected higher stromal PIBF expression in the endometrioid adenocarcinoma group as compared to the endometrial hyperplasia and normal endometrium groups (p < 0.001). The glandular PIBF expression did not differ among the groups (p > 0.05). Conclusions: Endometrial cancer cells have higher levels of expression of PIBF protein than normal endometrial tissue and endometrial hyperplasia tissue based on immunohistochemistry staining. PIBF immunostaining may be helpful in preoperatively differentiating between atypical endometrial hyperplasia (AEH) and endometrioid adenocarcinoma (EC) in suspicious cases.

Progesterone-induced blocking factor; PIBF, Endometrioid adenocarcinoma; Immunostaining

[1] Szekeres-Bartho J., Polgar B.: “PIBF: The double edged sword. Pregnancy and tumor”. Am J Reprod Immunol., 2010, 64, 77.

[2] Lachmann M., Gelbmann D., Kálmán E., Polgár B., Buschle M., Von Gabain A., et al.: “PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome”. Int. J. Cancer, 2014, 112, 51.

[3] Szekeres-Bartho J., Faust Z., Varga P., Szereday L., Kelemen K.: “The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production”. Am. J. Reprod. Immunol., 1996, 35, 348.

[4] Anderle C., Hammer A., Polgár B., Hartmann M., Wintersteiger R., Blaschitz A., et al.: “Human trophoblast cells express the immunomodulator progesterone-induced blocking factor”. J. Reprod. Immunol., 2008, 79, 26.

[5] Kyurkchiev D.S., Ivanova-Todorova E., Kyurkchiev. S.D.: “Effect of progesterone on human mesenchymal stem cells”. Vitam. Horm., 2011, 87, 217.

[6] Srivastava M.D., Thomas A., Srivastava B.I., Check J.H.: “Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone”. Leuk. Lymphoma, 2007, 48, 1610.

[7] Halasz M., Polgar B., Berta G., Czimbalek L., Szekeres-Bartho J.: “Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity”. Cell Mol. Life Sci., 2013, 70, 4617.

[8] Surveillance, Epidemiology, and End Results Program (SEER) (2016). Available at: https://seer.cancer.gov/statfacts/htlm/corp.html endometrial cancer

[9] Daniel A.R., Knutson T.P., Lange C.A.: “Signaling inputs to progesterone receptor gene regulation and promoter selectivity”. Mol. Cell Endocrinol., 2009, 308, 47.

[10] Szekeres-Bartho J., Faust Z., Varga P.: “The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes”. Am. J. Reprod. Immunol., 1995, 34, 342.

[11] González-Arenas A., Valadez-Cosmes P., Jiménez-Arellano C., López-Sánchez M., Camacho-Arroyo I.: “Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway”. J. Steroid Biochem. Mol. Biol., 2014, 144, 463.

[12] Dunn G.P., Old L.J., Schreiber R.D.: “The immunobiology of cancer immunosurveillance and immunoediting”. Immunity, 2004, 21, 137.

[13] Quezada S.A., Peggs K.S., Simpson TR., Allison J.P.: “Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication”. Immunol Rev., 2011, 241, 104.

[14] Ferguson A., Moore M., Fox H.: “Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: An immunohistological analysis of the tumour cells and infiltrating leucocytes”. Br. J. Cancer, 1985, 52, 551.

[15] Witkiewicz A.K., McConnell T., Potoczek M., Emmons R.V., Kurman R.J.: “Increased natural killer cells and decreased regulatory T cells are seen in complex atypicalendometrial hyperplasia and well-differentiated carcinoma treated with progestins”. Hum. Pathol., 2010, 41, 26.

[16] Miller C., Bidus M.A., Pulcini J.P., Maxwell G.L., Cosin J.A., Rose G.S.: “The ability of endometrial biopsies with atypical complex hyperplasia to guide surgical management”. Am. J. Obstet. Gynecol., 2008, 199, 69.

[17] Suh-Burgmann E, Hung YY, Armstrong MA. The value of additional pathology comments indicating suspicion of adenocarcinoma among women diagnosed preoperatively with complex atypical endometrial hyperplasia. Int. J. Gynecol. Pathol., 2012, 31, 222.

[18] American Joint Committee on Cancer: “Corpus uteri”. In: AJCC Staging Manual, 7th ed. New York: Springer, 2010.

[19] National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: “Uterine cancers”, 2008. Available at: http://www.nccn.org/professionals/physician_gls/fguidelines.asp?button=I+Agree

[20] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet, 2016, 387, 1094.